Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | RB1 | P06400 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21900686 | 0.80 | NR2E1 (0.67) | NR2E1HTR2AHTR2CKDM4EHPGD | |
| SCHEMBL833503 | 0.80 | NR2E1 (1.00) | NR2E1HTR2AHTR2CHPGDHSD17B10 | |
| SCHEMBL834930 | 0.80 | NR2E1 (1.00) | NR2E1HTR2AHTR2CHPGDHSD17B10 | |
| SCHEMBL700531 | 0.80 | NR2E1 (1.00) | NR2E1HTR2AHTR2CHPGDHSD17B10 | |
| SCHEMBL21754250 | 0.80 | NR2E1 (0.67) | NR2E1HTR2AHTR2CKDM4EHPGD | |
| SCHEMBL29670383 | 0.80 | NR2E1 (1.00) | NR2E1HTR2AHTR2CHPGDHSD17B10 | |
| SCHEMBL2515919 | 0.80 | NR2E1 (0.67) | NR2E1HTR2AHTR2CHPGDHSD17B10 | |
| SCHEMBL10746281 | 0.80 | NR2E1 (0.61) | NR2E1HTR2AHTR2CKDM4EHPGD | |
| Cyclindole SCHEMBL122715 | 0.80 | NR2E1 (0.61) | NR2E1HTR2AHTR2CKDM4EHPGD | |
| SCHEMBL23875668 | 0.79 | NR2E1 (0.65) | NR2E1HTR2AHTR2CKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3294712-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| EP-0731092-B1 | Process for producing substituted 1,2,3,4-tetrahydrocarbazoles | BAYER AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| US-5648500-A | Process for the preparation of substituted 1,2,3,4-tetrahydrocarbazoles | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-15 | — | — | US | disclosed |
| CN-1137521-A | Process for the preparation of subtituted 1,2,3,4-tetrahydrocarbazoles | BAYER AG (DE) | 1996-12-11 | — | — | CN | disclosed |
| EP-0731092-A1 | Process for producing substituted 1,2,3,4-tetrahydrocarbazoles | BAYER AG (DE) | 1996-09-11 | — | — | EP | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HCRTR1, CDR2, MSR1 | NR2E1 90/4885HTR2A 126/4885HTR2C 239/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | NR2E1 911/4885HTR2A 924/4885HTR2C 1753/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | NR2E1 911/4885HTR2A 924/4885HTR2C 1753/4885 |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | NR2E1 771/4885HTR2A 1012/4885HTR2C 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.